A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Phase 1
18+
Male only
8 sites in CA, FL, MA +4
What this study is about
This Phase 1 study is focused on people with metastatic castration resistant prostate cancer. The primary outcome being measured is Number of deaths.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of deaths, Number of participants with AEs leading to study intervention discontinuation, Number of participants with AEs meeting protocol defined dose limiting toxicity (DLT) criteria, Number of participants with adverse events (AEs), Number of participants with serious adverse events (SAEs)
Secondary: Area under the plasma concentration-time curve (AUC), Duration of response (DOR), Maximum concentration (Cmax), Number of participants with a confirmed prostate specific antigen decline of ≥ 30% from baseline response rate, Time of maximum concentration (Tmax)
Oncology